


Alpha Clinic Trial Test

Alpha Clinic Trials

Alpha Clinic ▼	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	B-Cell Leukemia	A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Eye - Retinopathy	Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy	Recruiting	
UC Davis & UCSD & UCSF	Deborah Stewart 916-703-9118 distewart@ucdavis.edu	UC Davis	HIV & Lymphoma	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Medeor Therapeutics	Kidney Transplant	Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Pluristem Ltd.	Muscle Injury - hip fracture	Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Cancer - Tongue Dysphagia	Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Kite Pharma	Advanced Cancer	A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Capricor Therapeutics	Muscle - Duchenne Muscular Dystrophy	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)	Recruiting	

UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Atara Bio.	EBV-PTLD	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Nohla Therapeutics	Cancer – Leukemia	Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML	Recruiting	
UC Davis		Orca Biosystems, Inc.	Hematologic Malignancies	A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Cancer - Lymphoma (HIV-Related)	Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Recruiting	
UCSF	Romobia Hutchinson 415-476-9326 romobia.hutchinson@ucsf.edu	UCSF	Blood Disorder - Alpha Thalassemia Major	In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)	Recruiting	
UCSF	Julie DeCaris 510-428-3885 ext 2739 jdecaris@mailcho.org	Seattle Children's Hospital Foundation	Cancer - Leukemia	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	Recruiting	
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mailcho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	Recruiting	
UCSF	Carol Fraser-Brown 415-476-2188 carolfraser-browne@ucsf.edu	Stanford University	Severe Combined Innunodeficiency (SCID)	AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients	Recruiting	
UCSF	Julie DeCaris 510-428-3885 ext.2739 jdecaris@mailcho.org	Bioerativ Therapeutics, Inc	Sickle Cell Disease	A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease	Recruiting	
UCSF & UCLA	Marci Moriarty, BSN, RN 510-428-3885 ext 5396 mmoriarty@mailcho.org Bruck Habtemariam 310-794-0242 bhabtemariam@mednet.ucla.edu	Sangamo Therapeutics	Blood Disorder - Beta-Thalassemia	A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)	Recruiting	

City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)	Recruiting	
City of Hope	Mihaela Cristea, MD 626-218-9200 mcristea@coh.org	Torque Therapeutics, Inc.	Cancer - Lymphoma	TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas	Recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)	Recruiting	
City of Hope	Lucy Ghoda 626-218-3605 lghoda@coh.org	City of Hope	Neurodegenerative Disorder	Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies	Recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)	Active, not recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1)	Recruiting	
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Leukemia	Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)	No longer active	
City of Hope	Erminia Massarelli 626-218-9200 emassarelli@coh.org	Tessa Therapeutics	Cancer - Nasopharyngeal Carcinoma	A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea	Recruiting	
City of Hope & UCLA	City of Hope: Amrita Krishnan, MD (626) 256-4673 ext 62405 AKrishnan@coh.org UCLA: Maricella Gonzalez 310-557-3729 mmgonzalez@mednet.ucla.edu	City of Hope	HIV/AIDS	Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients	Recruiting	
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Leukemia	Long-Term Follow-up Study for Patients Previously Treated With JCAR015	No longer active	

City of Hope	Behnam Badie, MD; 626-256-4673 bbadie@coh.org	City of Hope	Cancer - Brain	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma	Recruiting	
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Active, not recruiting	
City of Hope	Myo Htut, MD 626-218-2405 ext 82405 mhtut@coh.org	Juno Therapeutics	Cancer - Myeloma	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	Recruiting	
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas	Recruiting	
City of Hope	Joseph Rosenthal, MD 626-256-4673 ext 88442 jrosenthal@coh.org	City of Hope	Sickle Cell Disease	Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)	Recruiting	
City of Hope	Amrita Krishnan, MD (626) 256-4673 ext 62405 AKrishnan@coh.org	City of Hope	Cancer - Lymphoma (AIDS-Related)	Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma	Active, not recruiting	
City of Hope	Fatemeh Bidmeshki 626-218-9393 fbidmeshki@coh.org	City of Hope	Cancer - Brain	HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases	Recruiting	
City of Hope	Behnam Badie, MD (626) 256-4673 ext 60098 bbadie@coh.org	City of Hope	Cancer - Brain	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia A	Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A	Recruiting	
City of Hope	Cheryl De Guzman 626-218-5613 CDeGuzman@coh.org	Children's Hospital Los Angeles	Infection After Stem Cell Transplant	Antiviral Cellular Therapy for Enhancing T-cell Reconstitution	Recruiting	
City of Hope	Alex Herrera, MD 626-218-2405 aherrera@coh.org	Kite Pharma	Cancer - Lymphoma	Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)	Recruiting	
City of Hope	L. Elizabeth Budde, MD, PhD (626) 256-4673 ebudde@coh.org	City of Hope	Cancer - Leukemia	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	

City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Adaptimmune	Cancer - Myeloma	NY-ESO-1 ^{c259T} Alone and in Combination With Pembrolizumab for Multiple Myeloma	Recruiting	
City of Hope	Anthony Stein, MD 626-218-2405 stein@coh.org	Precision BioSciences, Inc.	Cancer - Lymphoma	Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10 ^{c796T} in Subjects With Stage IIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Active, not recruiting	
City of Hope	Leslie Popplewell, MD 626-218-2405 lpopplew@coh.org	Novartis Pharmaceuticals	Cancer - Lymphoma	Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC	Recruiting	
City of Hope	Rie Miyahira 626-256-4673 ext 80032 rmiyahira@coh.org	Angiocrine Bioscience	Cancer - Leukemia	A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation	Recruiting	
City of Hope	Karen Reckamp, MD 626-218-9200 kreckamp@coh.org	Glaxo Smith Kline (GSK)	Cancer - Lung	Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)- Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab	Recruiting	
City of Hope	Mihaela Cristea, MD (626) 256-4673 x89200 mcristea@coh.org	Adaptimmune	Cancer - Ovarian	A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.	Recruiting	
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Celgene	Cancer - Lymphoma	An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)	Recruiting	

Source URL: https://www.cirm.ca.gov/our-progress/alpha-clinic-trial-test?order=field_alpha_clinic&sort=desc